Alkermes reports FY2024 revenue $1.56B, net income $372M; guides FY2025 rev $1.34-$1.43B

Alkermes plc.

2024-FY EPS reported $2.17 revenue$1,557,632,000

FY2024 total revenues $1.56B, proprietary net sales up 18% YoY to $1.08B; GAAP diluted EPS from cont. ops $2.20.
Q4 proprietary net sales $307.7M: LYBALVI $77M (+37%), ARISTADA $96.6M (+16%), VIVITROL $134.1M (+31%).
Year-end cash/investments $824.8M; debt-free after retiring $290M debt; repurchased $200M shares in 2024.
FY2025 guidance: rev $1.34-$1.43B, GAAP net income $175-$205M, R&D spend up to $335M for pipeline.
ALKS 2680 Phase 2 narcolepsy data expected H2 2025; Phase 2 in idiopathic hypersomnia planned; ALKS 4510/7290 Phase 1 starts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.